The Gap:
Many metabolic enzymes remain difficult to target due to conserved active sites and competition with endogenous cofactors. 

The Approach:
We develop chemoproteomic approaches to uncover hidden, non-traditional binding sites that enable new modes of chemical modulation. 

The Output:
Chemical modulators of metabolic enzymes beyond conventional active-site inhibition, with applications across cancer, metabolic, and neurodegenerative diseases. 

The Gap:
Many tumors are “immune-cold” and respond poorly to immunotherapy due to immunosuppressive microenvironments.  

The Approach:
We develop chemical strategies to reprogram the tumor microenvironment and restore anti-tumor immune responses.

The Output:
Chemical ligands that enhance tumor immunogenicity and sensitize immune-evasive tumors to immunotherapy.  

The Gap:
Current drug discovery approaches largely focus on inhibition or degradation, leaving many aspects of protein function inaccessible to therapeutic intervention.  

The Approach:
We develop small molecules that induce proximity between proteins to reprogram protein function through mechanisms beyond degradation.

The Output:
Chemical modalities that enable new modes of protein modulation, with applications in cancer and infectious diseases.